Cardiff Oncology, Inc. will be hosting a conference call on May 2 at 4:30 p.m. ET/1:30 p.m. PT in San Diego to discuss their financial results for the first quarter ended March 31, 2024 and provide updates on their clinical programs targeting various indications such as colorectal cancer, pancreatic cancer, small cell lung cancer, and triple negative breast cancer.
During the call, Cardiff Oncology will highlight their lead asset, onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care therapeutics to target tumor vulnerabilities and deliver superior clinical benefit. The company is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers.
Interested individuals can listen to the live conference call by using the webcast link in the “Investors” section of the company’s website. A replay of the call will be available in the investor relations section on the website following its completion. To learn more about Cardiff Oncology and their clinical programs, visit their website at https://www.cardiffoncology.com/.
For any inquiries regarding financial information or investor relations, contact James Levine, Chief Financial Officer of Cardiff Oncology at 858-952-7670 or via email at jlevine@cardiffoncology.com. For media inquiries, please contact Grace Spencer from Taft Communications at 609-583-1151 or email grace@taftcommunications
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/BBNQJJJEXJEVPKBWNA6N25Z2GA.jpeg)
